Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials
Abstract
The pathogenesis of cutaneous lupus erythematosus (CLE) is multifactorial, and CLE is difficult to treat due to the heterogeneity of inflammatory processes among patients. Antimalarials such as hydroxychloroquine (HCQ) and quinacrine (QC) have long been used as first‐line systemic therapy; however, many patients do not respond to treatment with antimalarials and require systemic immunosuppressants that produce undesirable side effects. Given the complexity and the unpredictability of responses to antimalarial treatments in CLE patients, we sought to characterize the immunologic profile of patients with CLE stratified by subsequent treatment outcomes to identify potential biomarkers of inducible response.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2022
- Source ID
- 10.1002/art.42235
Entities
People
- D Yan
- Deanna Diaz
- Emily Keyes
- Felix Chin
- Grant Sprow
- Jay Patel
- Josh Dan
- Madison Grinnell
- Meena Sharma
- Rui Feng
- Thomas Vazquez
- Victoria Werth
- Yubin Li
Organizations
- Alliance for Lupus Research
- American College of Rheumatology Research and Education Foundation
- United States Department of Defense
- United States Department of Veterans Affairs
- University of Pennsylvania